Figure 1.
Representative Electrocardiograms From Patient(s) With BTK Inhibitor-Associated Arrhythmias
(A) A patient with the development of atrial fibrillation shortly after Bruton’s tyrosine kinase inhibitor (here ibrutinib) initiation. (B) A patient with ventricular arrhythmia development after Bruton’s tyrosine kinase inhibitor therapy.